Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for INHBE drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | INHBE ECD-Fc / Mutant Protein (HEK293 expressed, >95% purity, endotoxin <1EU/ug, native glycosylation, sequence verified) | View INHBE Products |
| Gene Delivery | INHBE Promise-ORF / Lentivirus (full-length ORF for stable cell lines) | View INHBE Products |
| Benchmark Ab | Anti-INHBE Neutralizing Antibody (recombinant positive control for ligand neutralization assays) | View INHBE Products |
| Validator | INHBE siRNA Set (for knockdown verification and specificity controls) | View INHBE Products |
| Receptor Complex | ACVR2B (Activin Receptor Type IIB) – primary receptor for INHBE signaling | View ACVR2B Products |
| Pathway Modulator | FST (Follistatin) – natural antagonist for assay calibration | View FST Products |
| Family Member | INHBA (Activin A) – related TGF-β family member for selectivity profiling | View INHBA Products |
| Related Target A | INHBC – closely related hepatokine for specificity counter-screening | View INHBC Products |
| Related Target B | ACVR1B – potential receptor interaction partner in metabolic signaling | View ACVR1B Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (Activin/Inhibin beta units) | Homolog panel proteins (INHBA, INHBB, INHBC) strictly verified by mass spec and high purity (>95%) |
| Evaluating secreted hepatokine interactions | HEK293 Expressed (Native Glycosylation), Endotoxin Controlled |
| Lack of controls | Clinical Benchmark Antibodies included |
| False positives in RNAi screening | Validated siRNA included for specificity checks |
| Proper disulfide-linked dimer formation (Activin E) | HEK293 expressed with native glycosylation; MW verified by mass spec |
| Heterodimer vs homodimer differentiation (Inhibin E vs Activin E) | Co-expression systems available; INHA companion proteins for heterodimer assembly validation |
| Receptor binding specificity (ACVR2A vs ACVR2B) | ACVR2A and ACVR2B recombinant ECD proteins for competitive binding assays |
| Functional specificity vs TGF-β family | Homolog panel (INHBA, INHBB, GDF11) for cross-reactivity screening |
Live INHBE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Metabolic Disease Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for INHBE therapeutics is intensifying. INHBE (Inhibin Subunit Beta E) is a hepatokine that forms homodimeric Activin E and heterodimeric Inhibin E complexes regulating energy metabolism and glucose homeostasis. Large-scale human genetics (e.g., UK Biobank) have linked loss-of-function mutations in INHBE to reduced abdominal fat, lower risk of type 2 diabetes and cardiovascular disease, making it an attractive target for metabolic disease. Major players include Regeneron (antibody), Alnylam and Arrowhead (siRNA). The next wave of R&D is targeting siRNA and monoclonal antibodies to phenocopy these protective mutations. Future trends point toward combination with GLP-1 receptor agonists to improve body composition (reducing visceral fat without muscle loss). As the field advances from target validation to lead optimization, demand for high-quality biochemical assays is surging.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / Gene Silencing | Alnylam, Arrowhead | Obesity, MASH, Hepatic Steatosis | Knockdown validation (need validated siRNA controls) |
| Monoclonal Antibody (Neutralizing) | Regeneron, Metabolic Biotechs | Metabolic Syndrome, Obesity, T2D | Target engagement (need HEK293 expressed INHBE with native conformation) |
| Small Molecule | Emerging Biotech | Type 2 Diabetes | Selectivity assay (need INHBC/Activin proteins for cross-reactivity panel) |
| Receptor-Fc Trap | Academic / Early Stage | NAFLD/NASH | Ligand capture efficiency (need oligomerization-competent ACVR2B-Fc) |